Physician profile
Hank Yang
NPI 1114946696
$48,503.03
in general payments reported to CMS, 2019-2025
75 companies · $5,379 in 2025
The $5,379 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,862 · 2020: $6,019 · 2021: $9,653 · 2022: $7,737 · 2023: $8,685 · 2024: $6,167 · 2025: $5,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Consulting Fee: $2,063 · Education: $526 · Travel and Lodging: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,172.51 |
| Consulting Fee | $2,062.50 |
| Education | $526.02 |
| Travel and Lodging | $470.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $6,268.89 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $3,889.92 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Janssen Biotech, INC. | $3,833.36 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Taiho Oncology, INC. | $2,801.88 | 2022-2025 | |
| Exelixis INC. | $2,659.07 | 2019-2025 | Cabometyx |
| Abbvie INC. | $2,525.99 | 2019-2025 | Venclexta |
| Pfizer INC. | $2,247.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,827.42 | 2019-2025 | |
| Genentech USA, INC. | $1,554.86 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Amgen INC. | $1,355.83 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Genzyme Corporation | $1,337.04 | 2019-2025 | |
| Lilly USA, LLC | $1,303.26 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $1,262.09 | 2019-2025 | Trodelvy |
| Incyte Corporation | $1,153.30 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $1,077.63 | 2019-2025 | Vyloy, Xospata, Padcev |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,063.41 | 2019-2025 | Reblozyl, Opdivo, Augtyro |
| Celgene Corporation | $945.39 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| Glaxosmithkline, LLC. | $822.64 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $775.69 | 2019-2025 | |
| Sobi, INC | $735.03 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $723.59 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Merck Sharp & Dohme LLC | $696.96 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Emd Serono, INC. | $646.83 | 2019-2025 | Bavencio |
| Daiichi Sankyo INC. | $610.16 | 2022-2025 | Enhertu, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $512.91 | 2019-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $403.98 | 2021-2025 | Libtayo |
| Stemline Therapeutics INC. | $383.74 | 2023-2025 | Orserdu, Elzonris |
| Alexion Pharmaceuticals, INC. | $372.66 | 2019-2024 | Ultomiris |
| Nestle Healthcare Nutrition INC. | $354.22 | 2021-2023 | |
| Pharmaessentia USA Corporation | $325.09 | 2022-2025 | Besremi |
| Dova Pharmaceuticals | $281.62 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $275.39 | 2022-2025 | Zepzelca |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.09 | 2019-2025 | Gilotrif |
| Kite Pharma, INC. | $238.04 | 2021-2025 | Yescarta |
| Array Biopharma INC | $235.78 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Secura Bio, INC. | $217.23 | 2020-2024 | Copiktra |
| Deciphera Pharmaceuticals INC. | $209.31 | 2022-2024 | Qinlock |
| Seagen INC. | $151.46 | 2022-2023 | Tukysa, Adcetris, Padcev |
| Epizyme, INC. | $134.35 | 2020-2021 | |
| Puma Biotechnology, INC. | $130.85 | 2019-2024 | |
| Mirati Therapeutics, INC. | $125.00 | 2023 | Krazati |
| Alnylam Pharmaceuticals INC. | $121.64 | 2021-2023 | Givlaari |
| Verastem, INC. | $118.72 | 2019 | |
| Clovis Oncology, INC. | $113.61 | 2019 | |
| Karyopharm Therapeutics INC. | $109.31 | 2022-2025 | Xpovio |
| Blueprint Medicines Corporation | $107.25 | 2022-2024 | Ayvakit |
| Genmab U.S., INC. | $102.37 | 2023-2025 | Epkinly |
| Agios Pharmaceuticals, INC. | $98.24 | 2024-2025 | Pyrukynd |
| Ipsen Biopharmaceuticals, INC | $85.43 | 2023-2024 | Somatuline Depot, Onivyde |
| Beigene USA, INC. | $82.12 | 2024 | Brukinsa |
| Tersera Therapeutics LLC | $77.45 | 2025 | Zoladex |
| Rigel Pharmaceuticals, INC. | $76.05 | 2022-2024 | Rezlidhia, Tavalisse |
| Adc Therapeutics America, INC. | $71.06 | 2023 | |
| Aadi Bioscience, INC. | $46.75 | 2023 | Fyarro |
| Dendreon Pharmaceuticals LLC | $41.32 | 2023-2025 | Provenge |
| Coherus Oncology, INC. | $39.44 | 2024-2025 | Loqtorzi |
| Aveo Pharmaceuticals, INC. | $38.96 | 2025 | |
| Morphosys, US INC. | $38.32 | 2021 | |
| Boston Scientific Corporation | $37.01 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Immunogen, INC. | $35.62 | 2023 | Elahere |
| Novocure INC. | $34.29 | 2024 | Optune Lua (Novottf-200t) |
| Macrogenics, INC. | $30.95 | 2022 | |
| Iovance Biotherapeutics, INC. | $30.71 | 2025 | Amtagvi |
| Janssen Pharmaceuticals, INC | $28.68 | 2019-2020 | |
| Springworks Therapeutics, INC. | $27.09 | 2024 | Ogsiveo |
| Pharmacosmos Therapeutics INC. | $24.24 | 2022 | |
| Servier Pharmaceuticals LLC | $24.04 | 2025 | |
| Apellis Pharmaceuticals, INC. | $22.88 | 2023 | Empaveli |
| Fennec Pharmaceuticals, INC. | $22.73 | 2024 | Pedmark |
| Immunomedics, INC. | $22.37 | 2020 | |
| Cti Biopharma Corp. | $21.07 | 2023 | Vonjo |
| Sun Pharmaceutical Industries INC. | $17.44 | 2019 | |
| Syndax Pharmaceuticals, INC. | $16.54 | 2025 | |
| Menarini Silicon Biosystems, INC. | $16.36 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hank Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.